Superworth

Enovis CORP EV/EBIT ENOV

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026
191×
10-year median
20.2×
Against its 10-year history
98th
percentile: 0 is its lowest day, 100 its highest
10-year range
13.2× to 216×
Peer median
25.5×

Enovis CORP's EV/EBIT is 191× as of Oct 23, 2026.

That is above its ten-year median of 20.2×, higher than on 98% of days in the last ten years.

Over that time it ranged from 13.2× in Oct 2016 to 216× in Aug 2026.

The median for 10 medical instruments and supplies stocks of a similar size is 25.5×.

EV/EBIT over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far191×176×216×
2025n/m a value too high to mean anything
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
202250.3×49.4×67.9×
202169.2×24.1×76.9×
202024.5×15.9×48.3×
201947.0×15.7×60.0×
201816.7×13.5×20.6×
201715.5×14.4×17.2×
201614.2×8.4×15.1×
20159.1×8.0×12.1×
201412.1×11.3×15.7×
201312.1×11.1×21.4×
201219.8×18.7×45.3×

Against its peers

Companies in Medical - Instruments & Supplies nearest Enovis CORP's size, closest first, today.

CompanyEV/EBIT
ENOVEnovis CORP191×
BVSBioventus26.2×
CDRECadre23.2×
STAAStaar Surgical57.7×
IRMDIradimed37.7×
EYENational Vision19.2×
LMATLemaitre Vascular22.6×
INSPInspire Medical Systems32.6×
MOVMovado11.8×
UFPTUFP Technologies24.9×
MDXGMimedx51.6×
Peer median25.5×

Where Enovis CORP ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Enovis CORP

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.